Investigators examined survival outcomes and recurrence patterns by pathologic nodal status in patients with upper tract urothelial carcinoma (UTUC) receiving neoadjuvant chemotherapy.

Tislelizumab combined with chemotherapy shows promising antitumor activity in advanced cervical cancer, achieving high response rates and manageable safety profiles.

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

For many cases of gastric (stomach) or gastroesophageal (GEJ) cancer, the standard treatment involves surgical removal of the malignant tissue, along with | Cancer ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Pediatric brain tumour prognosis has vastly and consistently improved in recent times. So, does the future hold promise for ...

Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a ...

A 73-year-old patient hailing from Myanmar who underwent a successful stomach cancer surgery at Shanghai East Hospital a ...

Anixa Biosciences' breast cancer vaccine elicited targeted immune responses in 70% of patients. Click here to read an ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...